The Delhi High Court has allowed Sun Pharma to manufacture and export its version of semaglutide, the diabetes and anti-obesity drug made by Novo Nordisk as Wegovy. However, the court barred Sun from selling the drug in India until March 2026, when Novo Nordisk’s secondary patent expires. Sun must file an affidavit and export account details, with the case next heard on February 19.
